Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

780
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
780
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

341
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
341
Bacterial Flora of the Large Intestine01:29

Bacterial Flora of the Large Intestine

1.2K
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
1.2K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

336
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
336
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

337
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
337
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

535
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
535

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Depression of tryptophan may contribute to adverse effects of naproxen.

Nature communications·2026
Same author

Concomitant COX-1 and COX-2 suppression is not sufficient to induce enteropathy associated with chronic NSAID use.

The Journal of clinical investigation·2026
Same author

Cleanet: Robust Doublet Detection in Cytometry Data Based on Protein Expression Patterns.

Cytometry. Part A : the journal of the International Society for Analytical Cytology·2025
Same author

Large-scale evaluation of proteomic and polygenic risk scores reveals complementary contributions to incident disease prediction.

medRxiv : the preprint server for health sciences·2025
Same author

Prostaglandins and the Cardiovascular System.

Arteriosclerosis, thrombosis, and vascular biology·2025
Same author

Sources of non-uniform coverage in short-read RNA-Seq data.

bioRxiv : the preprint server for biology·2025
Same journal

HER2-mutated lung squamous cell carcinoma responding to trastuzumab deruxtecan followed by pyrotinib: a Case Report.

Frontiers in pharmacology·2026
Same journal

Awareness, attitudes, and self-reported clinical management of antimicrobial-associated neurocognitive adverse effects among healthcare providers in Saudi Arabia.

Frontiers in pharmacology·2026
Same journal

Low-dose dasatinib in second-line therapy or beyond for the treatment of chronic-phase chronic myeloid leukemia: a real-world cohort study.

Frontiers in pharmacology·2026
Same journal

Natural products reshape osteosarcoma cell fate: promoting cell death.

Frontiers in pharmacology·2026
Same journal

<i>Leonurus japonicus</i> Houtt. extract containing isoquercitrin reduces airway inflammation in mice with allergic asthma.

Frontiers in pharmacology·2026
Same journal

Enhancing diabetes treatment by targeted nucleic acid and drug delivery using cell-penetrating peptides, peptide nucleic acids, and receptor targeting.

Frontiers in pharmacology·2026
See all related articles

Related Experiment Video

Updated: Dec 10, 2025

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
07:15

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

10.1K

NSAID-Gut Microbiota Interactions.

Damian Maseda1, Emanuela Ricciotti2

  • 1Department of Microbiology, University of Pennsylvania, Philadelphia, PA, United States.

Frontiers in Pharmacology
|August 28, 2020
PubMed
Summary
This summary is machine-generated.

The gut microbiota significantly impacts how nonsteroidal anti-inflammatory drugs (NSAIDs) work and their side effects. Understanding this interaction could lead to new ways to reduce NSAID-induced gut problems.

Keywords:
NSAIDS (nonsteroidal anti-inflammatory drugs)cyclooxygenasedysbiosisenteropathymicrobiota (microorganisms)prostanoid

More Related Videos

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
08:24

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

20.2K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.2K

Related Experiment Videos

Last Updated: Dec 10, 2025

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
07:15

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

10.1K
Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
08:24

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

20.2K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.2K

Area of Science:

  • Pharmacology
  • Microbiology
  • Gastroenterology

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) effectively treat pain and inflammation by inhibiting cyclooxygenase (COX) enzymes.
  • NSAID use is associated with significant gastrointestinal (GI) and cardiovascular (CV) risks, alongside considerable individual variability in response and adverse effects.
  • The gut microbiota plays a crucial role in host physiology, metabolism, and response to xenobiotics, including drugs.

Purpose of the Study:

  • To review the complex interplay between the host-gut microbiota and NSAIDs.
  • To explore how these interactions influence NSAID efficacy, disposition, and toxicity, particularly in the GI tract.
  • To highlight potential microbiota-based strategies for mitigating NSAID-induced enteropathy.

Main Methods:

  • Literature review of studies investigating the host-gut microbiota-NSAID axis.
  • Analysis of mechanisms by which gut microbes modify NSAIDs or influence host responses.
  • Examination of NSAID effects on gut microbiota composition and function.

Main Results:

  • Host-gut microbiota dynamics critically influence NSAID pharmacokinetics and pharmacodynamics.
  • Gut microbes can chemically alter NSAIDs or modulate host metabolism, affecting drug efficacy and toxicity.
  • NSAIDs can disrupt the gut microbiota, potentially leading to dysbiosis and exacerbating GI issues.
  • The bidirectional relationship between NSAIDs and gut microbiota contributes to inter-individual variability in drug response.

Conclusions:

  • The gut microbiota is a key determinant of NSAID efficacy and toxicity, especially GI complications.
  • Understanding the NSAID-microbiota interaction is essential for predicting and managing therapeutic outcomes.
  • Microbiota-targeted interventions show promise for preventing and treating NSAID-induced enteropathy.